TapewireFind a company

person · Reporting owner

Doogan Declan

Disclosed activity across 2 companies

Tapewire entity
69477
SEC CIK
0001704234

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
TENAX THERAPEUTICS, INC.TENX · Entity 979DirectorSeptember 16, 2026September 18, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

TENAX THERAPEUTICS, INC.

Report date September 16, 2026 · Filed September 18, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect55,274 Reported balance After 2026-09-16 transaction · row 1
1 source row

Row 1 · 2026-09-16 · Purchase · Acquired 53,000 · Balance 55,274

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.30 · Expires 2036-01-09Direct30,000 Reported balance Holding disclosure · report date 2026-09-16 · row 2 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 2 · Balance 30,000

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.75 · Expires 2035-07-01Direct80,000 Reported balance Holding disclosure · report date 2026-09-16 · row 3 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 3 · Balance 80,000

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.94 · Expires 2034-12-10Direct100,000 Reported balance Holding disclosure · report date 2026-09-16 · row 4 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 4 · Balance 100,000

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $992.00 · Expires 2032-06-09Direct4 Reported balance Holding disclosure · report date 2026-09-16 · row 5 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 5 · Balance 4

Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3,200.00 · Expires 2031-06-10Direct4 Reported balance Holding disclosure · report date 2026-09-16 · row 6 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 6 · Balance 4

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Biohaven Pharmaceutical Holding Co Ltd.

Report date December 31, 2021 · Filed February 11, 2022

Section 16 reporting ended · disclosed 2022-02-11. Current position is not established by this disclosure.

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common SharesSEC Table I · non-derivativeDirect0 Ending reported balance After 2021-11-30 transaction · row 28
4 source rows · reconciled sequence

Row 1 · 2021-03-08 · Gift · Disposed 210,000 · Balance 610,647

Row 12 · 2021-05-18 · Gift · Disposed 113,912 · Balance 496,735

Row 26 · 2021-11-22 · Gift · Disposed 491,260 · Balance 5,475

Row 28 · 2021-11-30 · Gift · Disposed 5,475 · Balance 0

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust140,000 Reported balance After 2021-03-08 transaction · row 2 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 2 · 2021-03-08 · Gift · Acquired 140,000 · Balance 140,000

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust84 Reported balance After 2021-03-18 transaction · row 7 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 7 · 2021-03-18 · Gift · Disposed 139,916 · Balance 84

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust132,985 Reported balance After 2021-03-24 transaction · row 11 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 11 · 2021-03-24 · Gift · Acquired 132,901 · Balance 132,985

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust246,897 Reported balance After 2021-05-18 transaction · row 13 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 13 · 2021-05-18 · Gift · Acquired 113,912 · Balance 246,897

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust278,437 Reported balance After 2021-05-18 transaction · row 14 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 14 · 2021-05-18 · Gift · Acquired 31,540 · Balance 278,437

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust108,437 Reported balance After 2021-05-21 transaction · row 18 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 18 · 2021-05-21 · Other · Disposed 170,000 · Balance 108,437

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust129,237 Reported balance After 2021-05-21 transaction · row 19 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 19 · 2021-05-21 · Gift · Acquired 20,800 · Balance 129,237

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust136,252 Reported balance After 2021-10-14 transaction · row 23 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 23 · 2021-10-14 · Gift · Acquired 7,015 · Balance 136,252

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust627,512 Reported balance After 2021-11-22 transaction · row 27 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 27 · 2021-11-22 · Gift · Acquired 491,260 · Balance 627,512

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan Revocable Trust632,987 Reported balance After 2021-11-30 transaction · row 29 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 29 · 2021-11-30 · Gift · Acquired 5,475 · Balance 632,987

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust70,000 Reported balance After 2021-03-08 transaction · row 3 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 3 · 2021-03-08 · Gift · Acquired 70,000 · Balance 70,000

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust9,225 Reported balance After 2021-03-16 transaction · row 5 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 5 · 2021-03-16 · Gift · Disposed 60,775 · Balance 9,225

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust31,540 Reported balance After 2021-03-22 transaction · row 9 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 9 · 2021-03-22 · Gift · Acquired 22,315 · Balance 31,540

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust52,340 Reported balance After 2021-05-18 transaction · row 16 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 16 · 2021-05-18 · Gift · Acquired 20,800 · Balance 52,340

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust20,800 Reported balance After 2021-05-18 transaction · row 17 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 17 · 2021-05-18 · Gift · Disposed 31,540 · Balance 20,800

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust0 Reported balance After 2021-05-21 transaction · row 21 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 21 · 2021-05-21 · Gift · Disposed 20,800 · Balance 0

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan Revocable Trust7,342 Reported balance After 2021-10-14 transaction · row 25 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 25 · 2021-10-14 · Gift · Acquired 7,342 · Balance 7,342

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan 2020 Trust60,775 Reported balance After 2021-03-16 transaction · row 4 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 4 · 2021-03-16 · Gift · Acquired 60,775 · Balance 60,775

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan 2020 Trust38,460 Reported balance After 2021-03-22 transaction · row 8 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 8 · 2021-03-22 · Gift · Disposed 22,315 · Balance 38,460

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan 2020 Trust17,660 Reported balance After 2021-05-18 transaction · row 15 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 15 · 2021-05-18 · Gift · Disposed 20,800 · Balance 17,660

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan 2020 Trust187,660 Reported balance After 2021-05-21 transaction · row 20 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 20 · 2021-05-21 · Other · Acquired 170,000 · Balance 187,660

Common SharesSEC Table I · non-derivativeIndirectDorothy Doogan 2020 Trust180,318 Reported balance After 2021-10-14 transaction · row 24 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 24 · 2021-10-14 · Gift · Disposed 7,342 · Balance 180,318

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan 2021 Trust139,916 Reported balance After 2021-03-18 transaction · row 6 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 6 · 2021-03-18 · Gift · Acquired 139,916 · Balance 139,916

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan 2021 Trust7,015 Reported balance After 2021-03-24 transaction · row 10 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 10 · 2021-03-24 · Gift · Disposed 132,901 · Balance 7,015

Common SharesSEC Table I · non-derivativeIndirectDeclan Doogan 2021 Trust0 Reported balance After 2021-10-14 transaction · row 22 Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source row

Row 22 · 2021-10-14 · Gift · Disposed 7,015 · Balance 0

Common SharesSEC Table I · non-derivativeIndirectBy the Declan Doogan 2014 Trust676,002 Reported balance Holding disclosure · report date 2021-12-31 · row 30 Holding and transaction disclosures are not merged.
1 source row

Row 30 · Balance 676,002

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 24, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 132,901 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 10

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Declan Doogan 2021 Trust

Disclosed balance after: 7,015

Read SEC document
March 22, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 22,315 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 9

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Dorothy Doogan Revocable Trust

Disclosed balance after: 31,540

Read SEC document
March 22, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 22,315 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 8

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Dorothy Doogan 2020 Trust

Disclosed balance after: 38,460

Read SEC document
March 18, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 139,916 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 7

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Declan Doogan Revocable Trust

Disclosed balance after: 84

Read SEC document
March 18, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 139,916 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 6

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Declan Doogan 2021 Trust

Disclosed balance after: 139,916

Read SEC document
March 16, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 60,775 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 5

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Dorothy Doogan Revocable Trust

Disclosed balance after: 9,225

Read SEC document
March 16, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 60,775 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Dorothy Doogan 2020 Trust

Disclosed balance after: 60,775

Read SEC document
March 08, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 70,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 3

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Dorothy Doogan Revocable Trust

Disclosed balance after: 70,000

Read SEC document
March 08, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 140,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · Declan Doogan Revocable Trust

Disclosed balance after: 140,000

Read SEC document
March 08, 2021 Filed Feb 11, 2022 21:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GiftCommon Shares 210,000 $0.00 $0.00
Disclosure

SEC source: 0001562180-22-001436 · primarydocument.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 610,647

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 300 $69.42 $20,825.01
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 8

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 626,002

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.39 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 25,208 $68.73 $1,732,457.61
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 7

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 626,302

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $69.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 31,920 $67.90 $2,167,514.83
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 6

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 651,510

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.37 - $68.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 16, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 2,572 $66.94 $172,161.71
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 5

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 683,430

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.36 - $67.35, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 16, 2020 Filed Feb 11, 2022 21:41 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 10,000 $68.97 $689,700.00
Disclosure

SEC source: 0001562180-22-001435 · primarydocument.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 323,912

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.77 - $69.45, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 16, 2020 Filed Feb 11, 2022 21:41 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 15,508 $68.58 $1,063,582.06
Disclosure

SEC source: 0001562180-22-001435 · primarydocument.xml · nonDerivative · entry 3

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 676,002

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $68.37 - $68.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 15,797 $68.10 $1,075,800.98
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 686,002

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 18,703 $67.51 $1,262,557.24
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 3

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 701,799

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.78 - $67.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 34,336 $66.05 $2,267,872.20
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 720,502

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 15, 2020 Filed Jun 17, 2020 21:55 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 11,164 $65.62 $732,560.47
Disclosure

SEC source: 0001562180-20-004574 · primarydocument.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 754,838

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.78 - $65.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 15, 2020 Filed Feb 11, 2022 21:41 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 13,334 $68.15 $908,742.77
Disclosure

SEC source: 0001562180-22-001435 · primarydocument.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 333,912

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.86 - $68.485, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 15, 2020 Filed Feb 11, 2022 21:41 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 2,464 $67.83 $167,126.71
Disclosure

SEC source: 0001562180-22-001435 · primarydocument.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 726,002

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.78 - $67.86, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 17, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 12, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 25,914 $65.78 $1,704,749.90
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 8

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 766,002

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 12, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 28,086 $64.79 $1,819,683.51
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 7

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 791,916

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.32 - $65.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 12, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 18,400 $63.90 $1,175,767.36
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 6

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 820,002

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.32 - $64.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 12, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 7,600 $62.93 $478,252.04
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 5

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 838,402

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.32 - $62.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 12, 2020 Filed Feb 11, 2022 21:40 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 13,334 $66.01 $880,114.67
Disclosure

SEC source: 0001562180-22-001434 · primarydocument.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 347,246

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.79 - $66.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 12, 2020 Filed Feb 11, 2022 21:40 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 12,580 $65.55 $824,635.35
Disclosure

SEC source: 0001562180-22-001434 · primarydocument.xml · nonDerivative · entry 3

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 792,669

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.32 - $65.79, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 25,039 $64.57 $1,616,873.39
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 846,002

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 18,474 $63.79 $1,178,530.36
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 3

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 871,041

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.31 - $64.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 20,043 $62.78 $1,258,207.34
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 889,515

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.31 - $63.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 11, 2020 Filed Jun 12, 2020 20:09 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 16,444 $61.97 $1,018,988.64
Disclosure

SEC source: 0001562180-20-004471 · primarydocument.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 909,558

F1 · kind: These sales were made pursuant to a 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.31 - $62.305, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

Read SEC document
June 11, 2020 Filed Feb 11, 2022 21:40 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 13,333 $64.71 $862,747.76
Disclosure

SEC source: 0001562180-22-001434 · primarydocument.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 360,580

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.54 - $65.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
June 11, 2020 Filed Feb 11, 2022 21:40 UTC Amendment Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 11,706 $64.42 $754,125.10
Disclosure

SEC source: 0001562180-22-001434 · primarydocument.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 859,335

F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.31 - $64.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.

F2 · ownership.direct: This amendment is being filed to correct the form of ownership reported in the original Form 4 filed on June 12, 2020. The original Form 4 inadvertently incorrectly reported that all common shares sold in the transactions reported on such Form 4 were indirectly held by the reporting person through the Declan Doogan 2014 Trust; however, as reflected in this amendment, a portion of the shares sold in certain transactions were in fact directly held by the reporting person. There were no other changes made to the information in the original filing.

Read SEC document
April 30, 2020 Filed May 1, 2020 21:14 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $47.10 $0.00
Disclosure

SEC source: 0001562180-20-003255 · primarydocument.xml · derivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2030-04-29

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) April 30, 2021 or (b) the date of the 2021 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
May 21, 2019 Filed May 23, 2019 18:33 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 GrantStock Option (Right to Buy) · Derivative 18,000 $0.00 Strike: $61.76 $0.00
Disclosure

SEC source: 0001209191-19-032463 · doc4.xml · derivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 18,000

Underlying: Common Shares · 18,000 shares

Expires 2029-05-20

F1 · derivative.exercise_date: The shares subject to this stock option will vest in full on the earlier of (a) May 21, 2020 or (b) the date of the 2020 Annual Meeting of Shareholders, in each case subject to the Reporting Person's continuous service with the Issuer through such vesting date.

Read SEC document
April 16, 2019 Filed Apr 16, 2019 19:23 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 50,000 $61.92 $3,096,000.00
Disclosure

SEC source: 0001209191-19-024835 · doc4.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 926,002

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.89 - $62.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
April 12, 2019 Filed Apr 16, 2019 19:23 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 38,825 $53.92 $2,093,444.00
Disclosure

SEC source: 0001209191-19-024835 · doc4.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 976,002

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.66 - $54.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
March 26, 2019 Filed Mar 26, 2019 18:30 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 5,824 $53.72 $312,865.28
Disclosure

SEC source: 0001209191-19-021354 · doc4.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 1,014,827

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.66 - $53.82, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
March 22, 2019 Filed Mar 26, 2019 18:30 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 5,351 $53.66 $287,134.66
Disclosure

SEC source: 0001209191-19-021354 · doc4.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 1,020,651

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
March 01, 2019 Filed Mar 1, 2019 17:59 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 50,000 $47.19 $2,359,500.00
Disclosure

SEC source: 0001209191-19-015151 · doc4.xml · nonDerivative · entry 6

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 1,026,002

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $47.01 - $47.88, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
March 01, 2019 Filed Mar 1, 2019 17:59 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 595 $45.41 $27,018.95
Disclosure

SEC source: 0001209191-19-015151 · doc4.xml · nonDerivative · entry 5

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 1,076,002

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 17:59 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 23,384 $45.71 $1,068,882.64
Disclosure

SEC source: 0001209191-19-015151 · doc4.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 1,076,597

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $46.12, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 17:59 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 1,900 $45.86 $87,134.00
Disclosure

SEC source: 0001209191-19-015151 · doc4.xml · nonDerivative · entry 3

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 373,913

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.75 - $46.045, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 17:59 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 18,270 $45.25 $826,717.50
Disclosure

SEC source: 0001209191-19-015151 · doc4.xml · nonDerivative · entry 2

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 375,813

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.75 - $45.685, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 27, 2019 Filed Mar 1, 2019 17:59 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 6,875 $44.17 $303,668.75
Disclosure

SEC source: 0001209191-19-015151 · doc4.xml · nonDerivative · entry 1

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 394,083

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.74 - $44.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 26, 2019 Filed Feb 26, 2019 17:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 100 $44.81 $4,481.00
Disclosure

SEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 6

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,958

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document
February 26, 2019 Filed Feb 26, 2019 17:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 20,796 $44.31 $921,470.76
Disclosure

SEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 5

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 401,058

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.79 - $44.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 25, 2019 Filed Feb 26, 2019 17:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 13,943 $45.49 $634,267.07
Disclosure

SEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 7

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By the Declan Doogan 2014 Trust

Disclosed balance after: 1,099,981

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $46.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.

Read SEC document
February 25, 2019 Filed Feb 26, 2019 17:44 UTC Biohaven Pharmaceutical Holding Co Ltd. BHVN · Entity 123269 SaleCommon Shares 100 $45.74 $4,574.00
Disclosure

SEC source: 0001209191-19-013671 · doc4.xml · nonDerivative · entry 4

Doogan Declan · CIK 0001704234 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 421,854

F1 · kind: These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.